Nils Lonberg, Ph.D.

Canaan Partners
Milpitas, CA

Dr. Nils Lonberg joined the venture capital firm Canaan Partners in 2019. 

He was the senior vice president of Biologics Discovery and head of Oncology Discovery at Bristol-Myers Squibb. Previously, Dr. Lonberg led a group that developed transgenic mice which have helped scientists discover effective new medicines for humans, including five FDA-approved antibody products. In recognition of his accomplishments, he was elected to the National Academy of Engineering. In addition to being a member of CRI’s Scientific Advisory Council, Dr. Lonberg serves on the Cancer Immunotherapy Consortium (CIC) Steering Committee.

I’m very proud of [our] Immuno-Oncology discovery team - years of their groundbreaking work have led to what is now widely recognized as a revolutionary time in cancer research.
Let's spread the word about Immunotherapy! Click to share this page with your community.

*Immunotherapy results may vary from patient to patient.

Top